{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:51:56Z","timestamp":1790621516545,"version":"4.1.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Br J Biomed Sci"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Publications on the associations of genetic variants with the response to platinum-based chemotherapy (PBC) in NSCLC patients have surged over the years, but the results have been inconsistent. Here, a comprehensive meta-analysis was conducted to combine eligible studies for a more accurate assessment of the pharmacogenetics of PBC in NSCLC patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Relevant publications were searched in PubMed, Scopus, and Web of Science databases through 15 May 2021. Inclusion criteria for eligible publications include studies that reported genotype and allele frequencies of NSCLC patients treated with PBC, delineated by their treatment response (sensitive vs. resistant). Publications on cell lines or animal models, duplicate reports, and non-primary research were excluded. Epidemiological credibility of cumulative evidence was assessed using the Newcastle-Ottawa Scale (NOS) and Venice criteria. Begg\u2019s and Egger\u2019s tests were used to assess publication bias. Cochran\u2019s Q-test and I<jats:sup>2<\/jats:sup> test were used to calculate the odds ratio and heterogeneity value to proceed with the random effects or fixed-effects method. Venice criteria were used to assess the strength of evidence, replication methods and protection against bias in the studies.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 121 publications comprising 29,478 subjects were included in this study, and meta-analyses were performed on 184 genetic variants. Twelve genetic variants from 10 candidate genes showed significant associations with PBC response in NSCLC patients with strong or moderate cumulative epidemiological evidence (increased risk: <jats:italic>ERCC1<\/jats:italic> rs3212986, <jats:italic>ERCC2<\/jats:italic> rs1799793, <jats:italic>ERCC2<\/jats:italic> rs1052555, and <jats:italic>CYP1A1<\/jats:italic> rs1048943; decreased risk: <jats:italic>GSTM1<\/jats:italic> rs36631, <jats:italic>XRCC1<\/jats:italic> rs1799782 and rs25487, <jats:italic>XRCC3<\/jats:italic> rs861539, <jats:italic>XPC<\/jats:italic> rs77907221, <jats:italic>ABCC2<\/jats:italic> rs717620, <jats:italic>ABCG2<\/jats:italic> rs2231142, and <jats:italic>CDA<\/jats:italic> rs1048977). Bioinformatics analysis predicted possible damaging or deleterious effects for <jats:italic>XRCC1<\/jats:italic> rs1799782 and possible low or medium functional impact for <jats:italic>CYP1A1<\/jats:italic> rs1048943.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our results provide an up-to-date summary of the association between genetic variants and response to PBC in NSCLC patients.<\/jats:p>","DOI":"10.3389\/bjbs.2024.11835","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:11:52Z","timestamp":1708488712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta\u2010Analysis"],"prefix":"10.3389","volume":"81","author":[{"given":"Hilary","family":"Sito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Ayub Khan","family":"Sharzehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Asiful","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing Cheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","article-title":"Non\u2013Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clinic Proc Mayo Clinic"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1002\/cncr.29045","article-title":"Analysis of Stage and Clinical\/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/PGPM.S286717","article-title":"Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort","volume":"14","author":"Machado-Rugolo","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/JTO.0b013e31811f3a7d","article-title":"Early Response to Platinum-Based First-Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Survival","volume":"2","author":"Sirohi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jtcvs.2006.10.019","article-title":"Chemotherapy Resistance and Oncogene Expression in Non-Small Cell Lung Cancer","volume":"133","author":"d\u2019Amato","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2217\/pgs-2016-0074","article-title":"Pharmacogenomics of Platinum-Based Chemotherapy Sensitivity in NSCLC: Toward Precision Medicine","volume":"17","author":"Yin","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fphar.2021.648407","article-title":"Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance","author":"Zheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17425255.2018.1416095","article-title":"Pharmacogenetics of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: Predictive Validity of Polymorphisms of ERCC1","volume":"14","author":"Hamilton","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e3010","DOI":"10.1002\/jgm.3010","article-title":"Low Penetrance Genetic Polymorphisms as Potential Biomarkers for Colorectal Cancer Predisposition","volume":"20","author":"Tan","year":"2018","journal-title":"J Gene Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/s41598-017-05642-0","article-title":"Genetic Polymorphisms and Platinum-Based Chemotherapy Treatment Outcomes in Patients With Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-Analysis","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18619","DOI":"10.1038\/s41598-021-97935-8","article-title":"The Rs9340799 Polymorphism of the Estrogen Receptor Alpha (ESR1) Gene and Its Association With Breast Cancer Susceptibility","volume":"11","author":"Tan","year":"2021","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104260","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.06.018","article-title":"Increased Spot Urine Albumin-To-Creatinine Ratio and Stroke Incidence: A Systematic Review and Meta-Analysis","volume":"28","author":"Huang","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/ije\/dym159","article-title":"Assessment of Cumulative Evidence on Genetic Associations: Interim Guidelines","volume":"37","author":"Ioannidis","year":"2008","journal-title":"Int J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B17","volume-title":"The HuGENet HuGE Review Handbook, Version 1.0","author":"Little","year":"2006"},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","article-title":"Imaging Biomarkers for Evaluating Tumor Response: RECIST and Beyond","volume":"9","author":"Ko","year":"2021","journal-title":"Biomark Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1038\/s41598-020-60442-3","article-title":"Association Between MIR499A Rs3746444 Polymorphism and Breast Cancer Susceptibility: A Meta-Analysis","volume":"10","author":"Tan","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3892\/or.2013.2696","article-title":"Predictive Value of ERCC1 and RRM1 Gene Single-Nucleotide Polymorphisms for First-Line Platinum- And Gemcitabine-Based Chemotherapy in Non-Small Cell Lung Cancer Patients","volume":"30","author":"Mlak","year":"2013","journal-title":"Oncol Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12253-018-0459-8","article-title":"Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients With Advanced NSCLC Treated With Cisplatin and Gemcitabine","volume":"25","author":"Mlak","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/oxfordjournals.aje.a000179","article-title":"Reporting, Appraising, and Integrating Data on Genotype Prevalence and Gene-Disease Associations","volume":"156","author":"Little","year":"2002","journal-title":"Am J Epidemiol"},{"key":"B23","year":"2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2016058","DOI":"10.4178\/epih.e2016058","article-title":"Meta-Analysis for Genome-Wide Association Studies Using Case-Control Design: Application and Practice","volume":"38","author":"Shim","year":"2016","journal-title":"Epidemiol Health"},{"key":"B25","year":"2024"},{"key":"B26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-801591-9.00002-3","article-title":"Relevant Cancer Diagnoses, Commonly Used Chemotherapy Agents and Their Biochemical Mechanisms of Action","volume-title":"Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity","author":"Grant","year":"2015"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1039\/d0sc00197j","article-title":"Interfering in Apoptosis and DNA Repair of Cancer Cells to Conquer Cisplatin Resistance by Platinum(iv) Prodrugs","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/ijms20174136","article-title":"New Insights Into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1007\/s13277-014-1866-4","article-title":"The Association Between the GSTP1 A313G and GSTM1 Null\/Present Polymorphisms and the Treatment Response of the Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients: A Meta-Analysis","volume":"35","author":"Yang","year":"2014","journal-title":"Tumour Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.gene.2013.05.021","article-title":"Association of ERCC1-C118T and -C8092A Polymorphisms With Lung Cancer Risk and Survival of Advanced-Stage Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: A Pooled Analysis Based on 39 Reports","volume":"526","author":"Xu","year":"2013","journal-title":"Gene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/cncr.26562","article-title":"Germline Polymorphisms in Patients With Advanced Nonsmall Cell Lung Cancer Receiving First-Line Platinum-Gemcitabine Chemotherapy: A Prospective Clinical Study","volume":"118","author":"Joerger","year":"2012","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single Nucleotide Polymorphisms and Outcome in Docetaxel-Cisplatin-Treated Advanced Non-Small-Cell Lung Cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3760\/cma.j.issn.0366-6999.2012.16.019","article-title":"A Meta-Analytic Review of ERCC1\/MDR1 Polymorphism and Chemosensitivity to Platinum in Patients With Advanced Non-Small Cell Lung Cancer","volume":"125","author":"Hai-bo","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.4238\/2014.October.31.14","article-title":"Effect of ERCC1 Polymorphism on the Response to Chemotherapy and Clinical Outcome of Non-Small Cell Lung Cancer","volume":"13","author":"Gao","year":"2014","journal-title":"Genet Mol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2014.07.023","article-title":"Pharmacogenetics of the DNA Repair Pathways in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy","volume":"353","author":"Sullivan","year":"2014","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2478\/18700","article-title":"Predictive Value of ERCC1 Single-Nucleotide Polymorphism in Patients Receiving Platinum-Based Chemotherapy for Locally-Advanced and Advanced Non-Small Cell Lung Cancer--A Pilot Study","volume":"50","author":"Krawczyk","year":"2012","journal-title":"Folia Histochem Cytobiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00432-011-1090-1","article-title":"A C118T Polymorphism of ERCC1 and Response to Cisplatin Chemotherapy in Patients With Late-Stage Non-Small Cell Lung Cancer","volume":"138","author":"Cheng","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.lungcan.2006.12.002","article-title":"Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer","volume":"56","author":"Su","year":"2007","journal-title":"Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e05919","DOI":"10.1016\/j.heliyon.2021.e05919","article-title":"The ECCR1 Rs11615, ERCC4 Rs2276466, XPC Rs2228000 and XPC Rs2228001 Polymorphisms Increase the Cervical Cancer Risk and Aggressiveness in the Bangladeshi Population","volume":"7","author":"Das","year":"2017","journal-title":"Heliyon"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/carcin\/bgn067","article-title":"A Distinct ERCC1 Haplotype Is Associated With mRNA Expression Levels in Prostate Cancer Patients","volume":"29","author":"Woelfelschneider","year":"2008","journal-title":"Carcinogenesis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2011.01.002","article-title":"The ERCC1 N118N Polymorphism Does Not Change Cellular ERCC1 Protein Expression or Platinum Sensitivity","volume":"708","author":"Gao","year":"2011","journal-title":"Mutat Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13277-011-0314-y","article-title":"Pharmacogenetic Role of ERCC1 Genetic Variants in Treatment Response of Platinum-Based Chemotherapy Among Advanced Non-Small Cell Lung Cancer Patients","volume":"33","author":"Yu","year":"2012","journal-title":"Tumour Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","article-title":"The Association Between the ERCC1\/2 Polymorphisms and the Clinical Outcomes of the Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis","volume":"35","author":"Yang","year":"2014","journal-title":"Tumour Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3892\/br.2014.282","article-title":"Nucleotide Excision Repair Gene Polymorphisms and Prognosis of Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: A Meta-Analysis Based on 44 Studies","volume":"2","author":"Huang","year":"2014","journal-title":"Biomed Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2018.01.011","article-title":"Combined Effect of ERCC1 and ERCC2 Polymorphisms on Overall Survival in Non-Squamous Non-Small-Cell Lung Cancer Patients Treated With First-Line Pemetrexed\/Platinum","volume":"118","author":"Liao","year":"2018","journal-title":"Lung Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1007\/s13277-013-1526-0","article-title":"Role of ERCC1 Variants in Response to Chemotherapy and Clinical Outcome of Advanced Non-Small Cell Lung Cancer","volume":"35","author":"Huang","year":"2014","journal-title":"Tumour Biol"},{"key":"B47","first-page":"843","article-title":"Association of an ERCC1 Polymorphism With Adult-Onset Glioma","volume":"9","author":"Chen","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1002\/cam4.1842","article-title":"Rs3212986 Polymorphism, a Possible Biomarker to Predict Smoking-Related Lung Cancer, Alters DNA Repair Capacity via Regulating ERCC1 Expression","volume":"7","author":"Yu","year":"2018","journal-title":"Cancer Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"180284","DOI":"10.1038\/sdata.2018.284","article-title":"Gene-Gene and Gene-Environment Interaction Data for Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer","volume":"5","author":"Wang","year":"2018","journal-title":"Scientific data"},{"key":"B50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43042-019-0034-1","article-title":"Gene-Environment and Gene-Gene Interactions Between CHRNA3 Rs1051730, XRCC1 Rs25487, and ERCC1 Rs735482 Variants Highly Elevate the Risk of Lung Cancer","volume":"20","author":"Ezzeldin","year":"2019","journal-title":"Egypt J Med Hum Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7643981","DOI":"10.1155\/2016\/7643981","article-title":"A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis","volume":"2016","author":"Han","year":"2016","journal-title":"Dis Markers"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.4238\/2014.April.29.9","article-title":"Association of Xeroderma Pigmentosum Group D (Asp312Asn, Lys751Gln) and Cytidine Deaminase (Lys27Gln, Ala70Thr) Polymorphisms With Outcome in Chinese Non-Small Cell Lung Cancer Patients Treated With Cisplatin-Gemcitabine","volume":"13","author":"Zhou","year":"2014","journal-title":"Genet Mol Res"},{"key":"B53","first-page":"1354","article-title":"Modulation of Nucleotide Excision Repair Capacity by XPD Polymorphisms in Lung Cancer Patients","volume":"61","author":"Spitz","year":"2001","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3748\/wjg.v26.i3.307","article-title":"Nucleotide Excision Repair Pathway Gene Polymorphisms Are Associated With Risk and Prognosis of Colorectal Cancer","volume":"26","author":"Li","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B55","first-page":"145","article-title":"XRCC1 Genetic Polymorphisms and Sensitivity to Platinum-Based Drugs in Non-Small Cell Lung Cancer: An Update Meta-Analysis Based on 4708 Subjects","volume":"8","author":"Gu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.4238\/2014.May.16.1","article-title":"Polymorphisms in the XRCC1 Gene Are Associated With Treatment Response to Platinum Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients Based on Meta-Analysis","volume":"13","author":"Li","year":"2014","journal-title":"Genet Mol Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1158\/1078-0432.CCR-11-1531","article-title":"Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis","volume":"18","author":"Wu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"16482","DOI":"10.1038\/srep16482","article-title":"Predictive Assessment in Pharmacogenetics of XRCC1 Gene on Clinical Outcomes of Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy","volume":"5","author":"Yuan","year":"2015","journal-title":"Scientific Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.7314\/apjcp.2012.13.9.4413","article-title":"Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-Small Cell Lung Cancer Patients","volume":"13","author":"Ke","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"B60","first-page":"196","article-title":"XRCC1 and XPD Genetic Polymorphisms Predict Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer","volume":"28","author":"Yuan","year":"2006","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3520764","DOI":"10.1155\/2020\/3520764","article-title":"Pharmacogenetic Association Between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients With NSCLC: A Meta-Analysis","volume":"2020","author":"Zhang","year":"2020","journal-title":"Biomed Res Int"},{"key":"B62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5732\/cjc.009.10139","article-title":"Correlation of the Sensitivity to Vinorelbine Plus Cisplatin (NP) Chemotherapy With Polymorphism in the DNA Repair Gene XRCC1 in Non-Small Lung Cancer","volume":"28","author":"Hong","year":"2009","journal-title":"Chin J Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.lungcan.2008.11.014","article-title":"Polymorphisms in XRCC1 and XPG and Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients","volume":"65","author":"Sun","year":"2009","journal-title":"Lung Cancer"},{"key":"B64","first-page":"14909","article-title":"Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln Gene Polymorphisms in the Clinical Outcome of Advanced Non-Small Cell Lung Cancer","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B65","first-page":"865","article-title":"Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer","volume":"23","author":"Wang","year":"2004","journal-title":"Chin J Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/0008-5472.CAN-09-3541","article-title":"Single Nucleotide Polymorphisms Inside Microrna Target Sites Influence Tumor Susceptibility","volume":"70","author":"Nicoloso","year":"2010","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7860\/jcdr\/2018\/36975.12000","article-title":"Breast Cancer Susceptibility Gene in Base Excision Repair Pathway in a Southern Indian Population","volume":"12","author":"Francis","year":"2018","journal-title":"J Clin Diagn Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cllc.2016.08.007","article-title":"Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery","volume":"18","author":"Santarpia","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e72251","DOI":"10.1371\/journal.pone.0072251","article-title":"Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"8","author":"Qiu","year":"2013","journal-title":"PLoS One"},{"key":"B70","first-page":"7430","article-title":"Functional Significance of XPD Polymorphic Variants: Attenuated Apoptosis in Human Lymphoblastoid Cells With the XPD 312 Asp\/Asp Genotype","volume":"61","author":"Seker","year":"2001","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3760\/j:issn:0376-2491.2005.14.011","article-title":"Polymorphisms in Nucleotide Excision Repair Genes XPC and XPD and Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer","volume":"85","author":"Yuan","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B72","first-page":"1510","article-title":"Correlation of Genetic Polymorphisms in Nucleotide Excision Repair System to Sensitivity of Advanced Non-Small Cell Lung Cancer Patients to Platinum-Based Chemotherapy","volume":"24","author":"Yuan","year":"2005","journal-title":"Chin J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.20900","article-title":"XPC Polymorphisms and Lung Cancer Risk","volume":"115","author":"Lee","year":"2005","journal-title":"Int J Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/carcin\/21.10.1821","article-title":"A New Xeroderma Pigmentosum Group C Poly(AT) Insertion\/Deletion Polymorphism","volume":"21","author":"Khan","year":"2000","journal-title":"Carcinogenesis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s41416-018-0307-3","article-title":"Cytidine Deaminase Enzymatic Activity Is a Prognostic Biomarker in Gemcitabine\/Platinum-Treated Advanced Non-Small-Cell Lung Cancer: A Prospective Validation Study","volume":"119","author":"Tibaldi","year":"2018","journal-title":"Br J Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Masters","year":"2015","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4149\/neo_2021_201116N1229","article-title":"Cytidine Deaminase 435C>T Polymorphism Relates to Gemcitabine-Platinum Efficacy and Hematological Toxicity in Chinese Non-Small-Cell Lung Cancer Patients","volume":"68","author":"Hu","year":"2021","journal-title":"Neoplasma"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/JTO.0b013e3182307e1f","article-title":"Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms With Response, Toxicity, and Survival in Cisplatin\/Gemcitabine-Treated Advanced Non-Small Cell Lung Cancer Patients","volume":"6","author":"Ludovini","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and Pharmacogenetics of Gemcitabine as a Mainstay in Adult and Pediatric Oncology: An EORTC-PAMM Perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4274\/tjps.28291","article-title":"Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients With Non-Small Cell Lung Cancer","volume":"14","author":"\u0130\u015fcan","year":"2017","journal-title":"Turk J Pharm Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"43397","DOI":"10.1371\/journal.pone.0043397","article-title":"CYP1A1 Ile462Val Polymorphism Contributes to Lung Cancer Susceptibility Among Lung Squamous Carcinoma and Smokers: A Meta-Analysis","volume":"7","author":"Ji","year":"2012","journal-title":"PLoS One"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1093\/carcin\/15.12.2961","article-title":"Functional Significance of Different Human CYP1A1 Genotypes","volume":"15","author":"Crofts","year":"1994","journal-title":"Carcinogenesis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/03602530701498026","article-title":"Recalling P446. P4501A1 (CYP1A1) Opting for Clinical Application","volume":"39","author":"Hildebrandt","year":"2007","journal-title":"Drug Metab Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0027-5107(01)00210-x","article-title":"Impact of Metabolic Genotypes on Levels of Biomarkers of Genotoxic Exposure","volume":"482","author":"Schoket","year":"2001","journal-title":"Mutat Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cbf.3577","article-title":"Increased ABCC2 Expression Predicts Cisplatin Resistance in Non-Small Cell Lung Cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cell Biochem Funct"},{"key":"B86","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3892\/or_00000721","article-title":"Multidrug Resistance-Associated Protein 2 Determines the Efficacy of Cisplatin in Patients With Hepatocellular Carcinoma","volume":"23","author":"Korita","year":"2010","journal-title":"Oncol Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","article-title":"Role of Multidrug Resistance Protein 2 (MRP2) in Chemoresistance and Clinical Outcome in Oesophageal Squamous Cell Carcinoma","volume":"104","author":"Yamasaki","year":"2011","journal-title":"Br J Cancer"},{"key":"B89","first-page":"3537","article-title":"Analysis of Expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, Homologues of the Multidrug Resistance-Associated Protein Gene (MRP1), in Human Cancer Cell Lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1523-1747.2003.12313.x","article-title":"Overexpression of cMOAT (MRP2\/ABCC2) Is Associated With Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin","volume":"121","author":"Liedert","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B91","first-page":"131","article-title":"The Correlation Between Single Nucleotide Polymorphism of ABC Transporter and Response Rate and Severe Toxicity in Lung Cancer Patients Treated With Platinum-Based Chemotherapy","volume":"16","author":"Qiao","year":"2016","journal-title":"Respirology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/cncr.22760","article-title":"Associations of ABCB1, ABCC2, and ABCG2 Polymorphisms With Irinotecan-Pharmacokinetics and Clinical Outcome in Patients With Advanced Non-Small Cell Lung Cancer","volume":"110","author":"Han","year":"2007","journal-title":"Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/tpj.2012.20","article-title":"Functional Characterization of ABCC2 Promoter Polymorphisms and Allele-Specific Expression","volume":"13","author":"Nguyen","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"B94","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/mol.109.058982","article-title":"The 5\u2032-Untranslated Region of Multidrug Resistance Associated Protein 2 (MRP2; ABCC2) Regulates Downstream Open Reading Frame Expression Through Translational Regulation","volume":"77","author":"Zhang","year":"2010","journal-title":"Mol Pharmacol"},{"key":"B95","first-page":"298","article-title":"Influence of Single Nucleotide Polymorphisms in ABCB1, ABCG2 and ABCC2 on Clinical Outcomes to Paclitaxel-Platinum Chemotherapy in Patients With Non-Small-Cell Lung Cancer","volume":"9","author":"Qiao","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1349-7006.2006.00371.x","article-title":"Re-Evaluation and Functional Classification of Non-Synonymous Single Nucleotide Polymorphisms of the Human ATP-Binding Cassette Transporter ABCG2","volume":"98","author":"Tamura","year":"2007","journal-title":"Cancer Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","article-title":"Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations","volume":"26","author":"Furukawa","year":"2009","journal-title":"Pharm Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bcp.2016.02.011","article-title":"The C421A (Q141K) Polymorphism Enhances the 3\u2019-Untranslated Region (3\u2019-UTR)-Dependent Regulation of ATP-Binding Cassette Transporter ABCG2","volume":"104","author":"Ripperger","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ijc.11669","article-title":"Single Nucleotide Polymorphisms Result in Impaired Membrane Localization and Reduced Atpase Activity in Multidrug Transporter ABCG2","volume":"109","author":"Mizuarai","year":"2004","journal-title":"Int J Cancer"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1023\/b:pham.0000045245.21637.d4","article-title":"Functional Analysis of SNPs Variants of BCRP\/ABCG2","volume":"21","author":"Kondo","year":"2004","journal-title":"Pharm Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-62703-435-7_15","article-title":"Methods to Examine the Impact of Nonsynonymous SNPs on Protein Degradation and Function of Human ABC Transporter","volume":"1015","author":"Ishikawa","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-018-0034-5","article-title":"Predicting Responses to Platin Chemotherapy Agents With Biochemically-Inspired Machine Learning","volume":"4","author":"Mucaki","year":"2019","journal-title":"Signal Transduction Targeted Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nrd2520","article-title":"Creating and Evaluating Genetic Tests Predictive of Drug Response","volume":"7","author":"Weiss","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"B104","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13578-023-01061-z","article-title":"The Genomic Signature of Resistance to Platinum-Containing Neoadjuvant Therapy Based on Single-Cell Data","volume":"13","author":"Sui","year":"2023","journal-title":"Cell Biosci"},{"key":"B105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-981-19-5082-7_10","article-title":"Economic Aspects in Precision Medicine and Pharmacogenomics","volume-title":"Precision Medicine in Clinical Practice","author":"Nosrati","year":"2022"},{"key":"B106","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2018.01.011","article-title":"Combined Effect of ERCC1 and ERCC2 Polymorphisms on Overall Survival in Non-Squamous Non-Small-Cell Lung Cancer Patients Treated With First-Line Pemetrexed\/Platinum","volume":"118","author":"Liao","year":"2018","journal-title":"Lung Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.1038\/s41598-020-64664-3","article-title":"Mitochondrial DNA Alterations May Influence the Cisplatin Responsiveness of Oral Squamous Cell Carcinoma","volume":"10","author":"Aminuddin","year":"2020","journal-title":"Scientific Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.2217\/fon-2018-0303","article-title":"Long Noncoding RNAs as Biotargets in Cisplatin-Based Drug Resistance","volume":"14","author":"Abu","year":"2018","journal-title":"Future Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1010327","DOI":"10.3389\/fgene.2022.1010327","article-title":"Insights on Variant Analysis in Silico Tools for Pathogenicity Prediction","volume":"13","author":"Garcia","year":"2022","journal-title":"Front Genet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13059-020-01954-z","article-title":"Comprehensive Assessment of Computational Algorithms in Predicting Cancer Driver Mutations","volume":"21","author":"Chen","year":"2020","journal-title":"Genome Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cells10082063","article-title":"Applying Bioinformatic Platforms, In Vitro, and In Vivo Functional Assays in the Characterization of Genetic Variants in the GH\/IGF Pathway Affecting Growth and Development","volume":"10","author":"Domen\u00e9","year":"2021","journal-title":"Cells"}],"container-title":["British Journal of Biomedical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/bjbs.2024.11835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:12:05Z","timestamp":1708488725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/bjbs.2024.11835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":111,"alternative-id":["10.3389\/bjbs.2024.11835"],"URL":"https:\/\/doi.org\/10.3389\/bjbs.2024.11835","relation":{},"ISSN":["2474-0896"],"issn-type":[{"value":"2474-0896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"article-number":"11835"}}